Which areas of pulmonary embolism (PE) treatment require further research and clinical trials?

Updated: Jun 06, 2019
  • Author: Daniel R Ouellette, MD, FCCP; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print
Answer

Advances over the past several decades have significantly improved physicians’ ability to diagnosis pulmonary embolism and have refined the treatment of this disorder. However, several areas need further research and properly conducted therapeutic trials. The role of LMWH and the optimal duration of anticoagulant therapy in different subgroups of patients with venous thromboembolism require further study.

Because warfarin therapy results in bleeding, future studies should determine whether less intense warfarin therapy is effective in preventing recurrences of pulmonary embolism.

Whether drugs that inhibit the action of thrombin (eg, hirudin) are useful in treating patients with venous thromboembolic disease also needs to be determined by future trials.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!